Rankings
▼
Calendar
ANIP Q1 2020 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ANIP
ANI Pharmaceuticals, Inc.
$2B
Q1 2020 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$50M
-5.9% YoY
Gross Profit
$28M
56.2% margin
Operating Income
-$8M
-15.8% margin
Net Income
-$7M
-14.1% margin
EPS (Diluted)
$-0.59
QoQ Revenue Growth
+3.8%
Cash Flow
Operating Cash Flow
$2M
Free Cash Flow
-$56M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$482M
Total Liabilities
$281M
Stockholders' Equity
$201M
Cash & Equivalents
$20M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$50M
$53M
-5.9%
Gross Profit
$28M
$38M
-26.7%
Operating Income
-$8M
$4M
-278.1%
Net Income
-$7M
$440,000
-1693.4%
Revenue Segments
Unapproved Products
$4M
100%
Geographic Segments
United States
$48M
97%
Canada
$2M
3%
← FY 2020
All Quarters
Q2 2020 →